Аннотация
Главной мишенью новой коронавирусной инфекции (COVID-19), распространяемой вирусом SARS-CoV-2, является дыхательная система. Однако по мере накопления данных о COVID-19 становится все более очевидным, что существует сложное взаимодействие между вирусом и иммунной системой, варьирующееся от умеренных и контролируемых реакций до выраженных и дисфункциональных мультитканевых направленных аутоиммунных реакций. Проведен поиск литературы о связи основных ревматических заболеваний с новой коронавирусной инфекцией COVID-19 в электронных поисковых системах PubMed, Scopus, eLIBRARY. Найденные литературные источники свидетельствуют, что новая коронавирусная инфекция COVID-19, безусловно, оказывает специфическое влияние на костно-суставно-мышечную систему в целом, и в частности на отдельные ревматические заболевания. В ряде исследований теоретические предпосылки о наличии ассоциации между основными ревматическими заболеваниями и COVID-19 получили клиническое подтверждение.
Ключевые слова: ревматические болезни, новая коронавирусная инфекция (COVID-19), пост-COVID-синдром, клиническая ассоциация, ревматоидный артрит, системная склеродермия, системная красная волчанка, артрит, гиперурикемия, подагра
Об авторе
Д.И. Трухан, И.А. Викторова
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
dmitry_trukhan@mail.ru
Список литературы
1. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630. [Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. DOI: 10.15829/1728- 88002020-2630 (in Russian).]
2. Novelli L, Motta F, De Santis M et al. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature. J Autoimmun 2021; 117: 102592. DOI: 10.1016/j.jaut.2020.102592
3. Киселева Е.П., Михайлопуло К.И., Новик Г.И., Сорока Н.Ф. Молекулярные механизмы инициирования и модуляции аутоиммунного процесса микроорганизмами. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021; 20 (1): 99–113. DOI: 10.24287/1726-1708-2021-20-1-99-113 [Kiseleva E.P., Mikhailopulo K.I., Novik G.I., Soroka N.F. Molecular mechanisms of induction and acceleration of autoimmunity by microorganisms. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2021; 20 (1): 99–113. DOI: 10.24287/1726-1708-2021-20-1- 99-113 (in Russian).]
4. Medhasi S, Chantratita N. Human Leukocyte Antigen (HLA) System: Genetics and Association with Bacterial and Viral Infections. J Immunol Res 2022; 2022: 9710376. DOI: 10.1155/2022/9710376
5. Augusto DG, Hollenbach JA. HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection. Curr Opin Immunol 2022; 76: 102178. DOI: 10.1016/j.coi.2022.102178
6. Hinojosa SS, Romero V. Risk HLA alleles in South America and potential new epitopes for SARS-CoV2. Hum Immunol 2021; 82 (8): 561–
7. DOI: 10.1016/j.humimm.2021.04.005 7. Migliorini F, Torsiello E, Spiezia F et al. Association between HLA genotypes and COVID-19 susceptibility, severity and progression: a comprehensive review of the literature. Eur J Med Res 2021; 26 (1): 84. DOI: 10.1186/s40001-021-00563-1
8. Bouayad A. Features of HLA class I expression and its clinical relevance in SARS-CoV-2: What do we know so far? Rev Med Virol 2021; 31 (6): e2236. DOI: 10.1002/rmv.2236
9. Deb P, Zannat KE, Talukder S et al. Association of HLA gene polymorphism with susceptibility, severity, and mortality of COVID-19: A systematic review. HLA 2022; 99 (4): 281–312. DOI: 10.1111/ tan.14560
10. Silva Andrade B, Siqueira S, de Assis Soares WR et al. Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses 2021; 13 (4): 700. DOI: 10.3390/v13040700
11. Dourmishev L, Guleva D, Pozharashka J et al. Autoimmune connective tissue diseases in the COVID-19 pandemic. Clin Dermatol. 2021; 39 (1): 56–63. DOI: 10.1016/j.clindermatol.2020.12.013
12. Favalli EG, Maioli G, Biggioggero M, Caporali R. Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Rev Clin Immunol 2021; 17 (6): 561–71. DOI: 10.1080/1744666X.2021.1908887
13. Favalli EG, Agape E, Caporali R. Incidence and Clinical Course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol 2020; 47 (8): 1296. DOI: 10.3899/jrheum.200507
14. Sarzi-Puttini P, Marotto D, Caporali R et al. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun 2021; 116: 102545. DOI: 10.1016/j.jaut.2020.102545
15. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis 2021; 80 (2): e18. DOI: 10.1136/annrheumdis-2020-217615
16. Pablos JL, Abasolo L, Alvaro-Gracia JM et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis 2020; 79: 1170–3. DOI: 10.1136/annrheumdis-2020-217763
17. Ferri C, Giuggioli D, Raimondo V et al.; COVID-19 & ASD Italian Study Group. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol 2020; 39 (11): 3195–204. DOI: 10.1007/s10067-020-05334-7
18. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 2020; Oct 13: annrheumdis-2020-218946. DOI: 10.1136/annrheumdis-2020-218946
19. Мазуров В.И., Беляева И.Б., Саранцева Л.Е. и др. Особенности клинического течения ревматических заболеваний у пациентов, перенесших новую коронавирусную инфекцию. Терапия. 2021; 10 (52): 42–54. DOI: 10.18565/therapy.2021.10.42-54 [Mazurov V.I., Beliaeva I.B., Sarantseva L.E. et al. Osobennosti klinicheskogo techeniia revmaticheskikh zabolevanii u patsientov, perenesshikh novuiu koronavirusnuiu infektsiiu. Terapiia. 2021; 10 (52): 42–54. DOI: 10.18565/therapy.2021.10.42-54 (in Russian).]
20. Fredi M, Cavazzana I, Moschetti L et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol 2020; 2 (9): e549–556. DOI: 10.1016/S2665-9913(20)30169-7
21. Haberman R, Axelrad J, Chen A et al. COVID-19 in immune-mediated inflammatory diseases – Case series from New York. N Engl J Med 2020; 383 (1): 85–8. DOI: 10.1056/NEJMc2009567
22. Scirè CA, Carrara G, Zanetti A et al. COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol 2020; 38 (4): 748–53. https://pubmed.ncbi.nlm.nih.gov/32723435/
23. Elemam NM, Maghazachi AA, Hannawi S. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. Curr Med Res Opin 2021; 37 (6): 929–8. DOI: 10.1080/03007995.2021.1906637
24. Wang Y, D'Silva KM, Jorge AM et al. Increased Risk of COVID-19 in Patients With Rheumatoid Arthritis: A General Population-Based Cohort Study. Arthritis Care Res (Hoboken) 2021. DOI: 10.1002/acr.24831
25. Malek Mahdavi A, Varshochi M, Hajialilo M et al. Factors associated with COVID-19 and its outcome in patients with rheumatoid arthritis. Clin Rheumatol 2021; 40 (11): 4527–31. DOI: 10.1007/s10067- 021-05830-4
26. Hasseli R, Pfeil A, Hoyer BF et al. Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis? Clin Exp Rheumatol 2021; 39 (3): 639–47. URL: https://pubmed.ncbi.nlm.nih.gov/33822706/
27. England BR, Roul P, Yang Y et al. Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in AtRisk Individuals. Arthritis Rheumatol 2021; 73 (12): 2179–88. DOI: 10.1002/art.41800
28. Raiker R, DeYoung C, Pakhchanian H et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum 2021; 51 (5): 1057– 66. DOI: 10.1016/j.semarthrit.2021.08.010
29. Curtis JR, Zhou X, Rubin DT et al. Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. J Rheumatol 2022; 49 (3): 320–9. DOI: 10.3899/jrheum. 210888
30. Topless RK, Phipps-Green A, Leask M et al. Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. ACR Open Rheumatol 2021; 3 (5): 333– 40. DOI: 10.1002/acr2.11252
31. D'Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol 2021; 33 (3): 255–61. DOI: 10.1097/ BOR.0000000000000786
32. Mochizuki T, Yano K, Ikari K, Okazaki K. Effects of the COVID-19 pandemic on body composition among patients with rheumatoid arthritis. Mod Rheumatol 2022; 32 (2): 452–4. DOI: 10.1093/mr/roab018
33. Трухан Д.И., Иванова Д.С., Белус К.Д. Ревматоидный артрит и традиционные кардиоваскулярные факторы риска: актуальные аспекты реальной клинической практики. Consilium Medicum. 2020; 22 (1): 19–25. DOI: 10.26442/20751753. 2020.1.200052 [Trukhan D.I., Ivanova D.S., Belus K.D. Rheumatoid arthritis and traditional cardiovascular risk factors: actual aspects of real clinical practice. Consilium Medicum. 2020; 22 (1): 19–25. DOI: 10.26442/20751753.2020.1.200052 (in Russian).]
34. Трухан Д.И., Иванова Д.С., Белус К.Д. Ревматоидный артрит: влияние воспаления и противовоспалительной терапии на кардиоваскулярные факторы риска. Медицинский совет. 2020; 11: 32–44. DOI: 10.21518/2079-701X2020-11-32-44 [Trukhan D.I., Ivanova D.S., Belus K.D. Revmatoidnyi artrit: vliianie vospaleniia i protivovospalitel'noi terapii na kardiovaskuliarnye faktory riska. Meditsinskii sovet. 2020; 11: 32–44. DOI: 10.21518/2079- 701X2020-11-32-44 (in Russian).]
35. Matucci-Cerinic M, Hughes M, Taliani G, Kahaleh B. Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral" challenge for future research in scleroderma. Autoimmun Rev 2021; 20 (10): 102899. DOI: 10.1016/j.autrev.2021.102899
36. Blicharz L, Czuwara J, Samochocki Z et al. Immunosuppressive treatment for systemic sclerosis-Therapeutic challenges during the COVID-19 pandemic. Dermatol Ther 2020; 33 (4): e13619. DOI: 10.1111/dth.13619
37. Matucci-Cerinic M, Bruni C, Allanore Y et al. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis. 2020;79 (6): 724–6. DOI: 10.1136/annrheumdis-2020-217407
38. Ferro F, Elefante E, Puxeddu I et al. COVID-19: the new challenge for rheumatologists. First update. Clin Exp Rheumatol. 2020; 38 (3): 373–82. URL: https://pubmed.ncbi.nlm.nih.gov/32452355/
39. Orlandi M, Landini N, Bruni C et al. Infection or Autoimmunity? The Clinical Challenge of Interstitial Lung Disease in Systemic Sclerosis During the COVID-19 Pandemic. J Rheumatol 2021; 48 (5): 790–2. DOI: 10.3899/jrheum.200832
40. Orlandi M, Lepri G, Bruni C et al. The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clin Rheumatol 2020; 39 (7): 2043–7. DOI: 10.1007/s10067-020-05193-2
41. Matucci-Cerinic M, Bruni C, Allanore Y et al. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis 2020; 79 (6): 724–6. DOI: 10.1136/annrheumdis-2020-217407
42. Avouac J, Airó P, Carlier N et al. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis 2020. DOI: 10.1136/annrheumdis-2020-217864
43. Трухан Д.И., Филимонов С.Н., Багишева Н.В. Болезни органов дыхания: актуальные аспекты клиники, диагностики и лечения. СПб.: СпецЛит, 2022. URL: https://www.elibrary.ru/item.asp?id=49459552 [Trukhan D.I., Filimonov S.N., Bagisheva N.V. Bolezni organov dykhaniia: aktual'nye aspekty kliniki, diagnostiki i lecheniia. Saint Petersburg: SpetsLit, 2022. URL: https://www.elibrary.ru/item. asp?id=49459552 (in Russian).]
44. Muniz BC, Milito MA, Marchiori E. COVID-19 – Computed tomography findings in two patients in Petrópolis, Rio de Janeiro, Brazil. Rev Soc Bras Med Trop 2020; 53: e20200147. DOI: 10.1590/0037-8682- 0147-2020
45. Трухан Д.И. Новая коронавирусная инфекция (COVID-19) и заболевания / патологические состояния органов дыхания. Медицинский совет. 2022; 16 (18): 88–95. DOI: 10.21518/2079-701X2022-16-18-88-95 [Trukhan D.I. Novaia koronavirusnaia infektsiia (COVID-19) i zabolevaniia / patologicheskie sostoianiia organov dykhaniia. Meditsinskii sovet. 2022; 16 (18): 88–95. DOI: 10.21518/2079-701X-2022-16- 18-88-95 (in Russian).]
46. Mariano RZ, Rio APTD, Reis F. Covid-19 overlapping with systemic sclerosis. Rev Soc Bras Med Trop 2020; 53: e20200450. DOI: 10.1590/0037-8682-0450-2020
47. Fineschi S. Case Report: Systemic Sclerosis After Covid-19 Infection. Front Immunol 2021; 12: 686699. DOI: 10.3389/fimmu.2021. 686699
48. Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res 2021; 232: 13–36. DOI: 10.1016/ j.trsl.2020.12.007
49. Marks M, Marks JL. Viral arthritis. Clin Med (Lond) 2016; 16 (2): 129–34. DOI: 10.7861/clinmedicine.16-2-129
50. Guan W, Ni Z, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–20. DOI: 10.1056/NEJMoa2002032
51. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol 2020; 82 (5):e 177. DOI: 10.1016/j.jaad.2020.03.036
52. Zeidler H. Post-Corona-Virus-Disease-19 arthritis. Manifestation under the clinical picture of a reactive arthritis. Z Rheumatol 2021; 80 (6): 555–8. DOI: 10.1007/s00393-021-01045-9
53. Каратеев А.Е. Суставной синдром при COVID-19: от артралгий до ревматоидного артрита. Терапия. 2022; 2 (54): 24–31. DOI: 10.18565/therapy.2022.2.24-31 [Karateev A.E. Sustavnoi sindrom pri COVID-19: ot artralgii do revmatoidnogo artrita. Terapiia. 2022; 2 (54): 24–31. DOI: 10.18565/therapy.2022.2.24-31 (in Russian).]
54. Тарадин Г.Г., Куглер Т.Е., Маловичко И.С., Кононенко Л.В. Острый артрит, ассоциированный с COVID-19. Альманах клинической медицины. 2022; 50 (2): 139–48. DOI: 10.18786/2072-0505- 2022-50-015 [Taradin G.G., Kugler T.E., Malovichko I.S., Kononenko L.V. Ostryi artrit, assotsiirovannyi s COVID-19. Al'manakh klinicheskoi meditsiny. 2022; 50 (2): 139–48. DOI: 10.18786/2072-0505-2022-50-015 (in Russian).]
55. Сухова Т.Е., МолочковаЮ.В.,Карташова М.Г.,Карзанов О.В. Изменение течения псориаза после перенесенного заболевания COVID19. Серия клинических наблюдений. Альманах клинической медицины. 2021; 49 (8): 550–7. DOI: 10.18786/2072-0505-2021-49-065 [Sukhova T.E., Molochkova Iu.V., Kartashova M.G., Karzanov O.V. Changes in the clinical course of psoriasis post-COVID-19: a clinical case series. Al'manakh klinicheskoi meditsiny. 2021; 49 (8): 550–7. DOI: 10.18786/2072-0505-2021-49-065 (in Russian).]
56. Nørgård BM, Zegers FD, Nielsen J, Kjeldsen J. Post COVID-19 hospitalizations in patients with chronic inflammatory diseases – A nationwide cohort study. J Autoimmun 2021; 125: 102739. DOI: 10.1016/j.jaut.2021.102739
57. Chauhan K, Pattharanitima P, Piani F et al. Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19. Am J Nephrol 2022; 53 (1): 78–86. DOI: 10.1159/ 000520355
58. Chen B, Lu C, Gu HQ et al. Serum Uric Acid Concentrations and Risk of Adverse Outcomes in Patients With COVID-19. Front Endocrinol (Lausanne) 2021; 12: 633767. DOI: 10.3389/fendo.2021.633767
59. Shamantha G, Balaraj K, Prabhu R et al. Can Uric Acid be Used as a Prognostic Factor to Determine the Severity of Covid 19 Infection. J Assoc Physicians India 2022; 70 (4): 11–2. URL: https://pubmed.ncbi.nlm.nih.gov/35443479/
60. Zheng T, Liu X, Wei Y et al. Laboratory Predictors of COVID-19 Mortality: A Retrospective Analysis from Tongji Hospital in Wuhan. Mediators Inflamm 2021; 2021: 6687412. DOI: 10.1155/2021/6687412
61. Dalbeth N, Robinson PC. Patients with gout: an under-recognised group at high risk of COVID-19. Lancet Rheumatol 2021; 3 (5): e317– e318. DOI: 10.1016/S2665-9913(21)00073-4
62. Tai V, Robinson PC, Dalbeth N. Gout and the COVID-19 pandemic. Curr Opin Rheumatol 2022; 34 (2): 111–7. DOI: 10.1097/ BOR.0000000000000860
63. Jatuworapruk K, Montgomery A, Gianfrancesco M et al. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. ACR Open Rheumatol 2022:10.1002/acr2.11495. DOI: 10.1002/acr2.11495
64. Topless RK, Gaffo A, Stamp LK et al. Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. Lancet Rheumatol 2022; 4 (4): e274–281. DOI: 10.1016/S2665- 9913(21)00401-X
65. Xie D, Choi HK, Dalbeth N et al. Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study. Arthritis Rheumatol 202: 10.1002/art.42339. DOI: 10.1002/art.42339
66. Hase R, Kurata R, Ishida K et al. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. Intern Med 2020; 59 (18): 2327–9. DOI: 10.2169/internalmedicine.5377-20
67. Koseki T, Nakajima K, Iwasaki H et al. Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. Int J Infect Dis 2022; 115: 218–23. DOI: 10.1016/j.ijid.2021.12.324
68. Mishima E, Anzai N, Miyazaki M et al. Uric Acid Elevation by Favipiravir, an Antiviral Drug. Exp Med 2020; 251 (2): 87–90. DOI: 10.1620/tjem.251.87
69. Hung DT, Ghula S, Aziz JMA et al. The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. Int J Infect Dis 2022; 120: 217–27. DOI: 10.1016/j.ijid.2022.04.035
70. Pelechas E, Drossou V, Voulgari PV, Drosos AA. COVID-19 in patients with gout on colchicine. Rheumatol Int 2021; 41 (8): 1503–7. DOI: 10.1007/s00296-021-04902-7
71. Reyes AZ, Hu KA, Teperman J et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis 2021; 80 (5): 550–7. DOI: 10.1136/annrheumdis-2020-219174
72. Tardif JC, Bouabdallaoui N, L'Allier PL et al.; COLCORONA Investigators. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 2021; 9 (8): 924–32. DOI: 10.1016/S2213-2600(21)00222-8
73. Al-Kuraishy HM, Hussien NR, Al-Niemi MS, Al-Gareeb AI. Colchicine in the management of Covid-19: With or lieu of evidence. J Pak Med Assoc 2021; 71 (Suppl. 8) 12: S127-S132. URL: https://pubmed.ncbi.nlm.nih.gov/35130235/
74. Ferri C, Ursini F, Gragnani L et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups. J Autoimmun 2021; 125: 102744. DOI: 10.1016/j.jaut.2021.102744.
75. Sattui SE, Liew JW, Kennedy K et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021; 7e001814. DOI: 10.1136/rmdopen-2021-001814
76. Ciaffi J, Giuggioli D, Mari A et al. COVID-19 vaccine hesitancy in systemic sclerosis. Clin Exp Rheumatol 2021; 39: 165–6. DOI: 10.55563/clinexprheumatol/vv61xv
77. Gordon JK, Showalter K, Wu Y et al.; SPIN COVID-19 Patient Advisory Team on behalf of the SPIN Investigators. Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study. Lancet Rheumatol 2022; Jan 18. DOI: 10.1016/S2665-9913(21)00416-1
78. Oka Y, Kodera T, Takeshita M et al. Decrease of infectious complications in outpatients with autoimmune diseases from 2019 to 2020 under the COVID-19 pandemic: A single-centre, retrospective cohort study in Japan. Mod Rheumatol 2022; 32 (2): 444–51. DOI: 10.1093/mr/roab080
79. Venkatesan P. NICE guideline on long COVID. Lancet Respirator Med 2021; 9 (2): 129. DOI: 10.1016/S2213-2600(21)00031-X
80. Zacharias H, Dubey S, Koduri G, D'Cruz D. Rheumatological complications of Covid 19. Autoimmun Rev 2021; 20 (9): 102883. DOI: 10.1016/j.autrev.2021.102883
81. Silva Andrade B, Siqueira S, de Assis Soares WR et al. Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses 2021; 13 (4): 700. DOI: 10.3390/v13040700
82. Taha SI, Samaan SF, Ibrahim RA et al. Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity? Eur Cytokine Netw 2021; 32 (4): 83–8. DOI: 10.1684/ecn.2021.0471
83. Мазуров В.И., Беляева И.Б., Саранцева Л.Е. и др. Особенности клинического течения ревматических заболеваний у пациентов, перенесших новую коронавирусную инфекцию. Терапия. 2021; 10 (52): 42–54. DOI: 10.18565/therapy.2021.10.42-54 [Mazurov V.I., Beliaeva I.B., Sarantseva L.E. et al. Osobennosti klinicheskogo techeniia revmaticheskikh zabolevanii u patsientov, perenesshikh novuiu koronavirusnuiu infektsiiu. Terapiia. 2021; 10 (52): 42–54. DOI: 10.18565/therapy.2021.10.42-54 (in Russian).]
84. Bhadelia N, Belkina AC, Olson A et al. Distinct autoimmune antibody signatures between hospitalized acute COVID-19 patients, SARS-CoV-2 convalescent Individuals, and unexposed pre-pandemic controls. medRxiv 2021.01.21.21249176. DOI: 10.1101/2021. 01.21.21249176
85. Насонов Е.Л., Попкова Т.В., Панафидина Т.А. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021; 59 (2): 119–28. DOI: 10.47360/1995-4484-2021-119-128 [Nasonov E.L., Popkova T.V., Panafidina T.A. Problemy rannei sistemnoi krasnoi volchanki v period pandemii COVID-19. Nauchnoprakticheskaia revmatologiia. 2021; 59 (2): 119–28. DOI: 10.47360/1995-4484-2021-119-128 (in Russian).]
86. Su Y, Yuan D, Chen DG et al. Multiple early factors anticipate postacute COVID-19 sequelae. Cell 2022; 185 (5): 881–95.e20. DOI: 10.1016/j.cell.2022.01.014
Для цитирования:Трухан Д.И., Викторова И.А. Новая коронавирусная инфекция (COVID-19) и основные ревматические заболевания. Клинический разбор в общей медицине. 2023; 4 (1): 36–43. DOI: 10.47407/kr2023.4.1.00187
Журнал предоставляет свободный доступ с возможностью использовать статьи в некоммерческих целях при условии указания авторства в рамках лицензии CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ru)